Narcolepsy

M. Zarowski, T. Ali-Dinar, S. V. Kothare

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Narcolepsy is a life-long neurological, rapid eye movement (REM) sleep disorder characterized by excessive daytime sleepiness, REM intrusions in wakefulness and sleep, and abnormal sleep-wake cycle regulation. Additional symptoms include sleep maintenance insomnia, REM sleep behavior disorders, obstructive sleep apnea, periodic limb movement, weight gain, migraines, and depression. Narcolepsy is not an uncommon disorder, but is underrecognized. It has an estimated prevalence of 0.05%. The age of onset shows two peaks of presentation: in childhood and in adults. Both genetics and environmental factors may be involved in the development of narcolepsy. The history, combined with polysomnography and Multiple Sleep Latency Test, remain the current gold standard in the diagnosis of narcolepsy. Human leukocyte antigen (HLA) typing shows an association with HLA DQB1*0602 in more than 92% of cases. The levels of Hypocretin-1 are undetectable in the cerebrospinal fluid in most patients with narcolepsy with cataplexy. It is highly specific (99.1%) and sensitive (88.5%) for narcolepsy with cataplexy but can also be positive in the normal population (25-30%). Early recognition and treatment can greatly improve the quality of life of patients with narcolepsy. Treatment of narcolepsy includes non-pharmacological (life style changes) and pharmacological (stimulants, modafinil, sodium oxybate) treatment against hypersomnia and anti-cataplectic drugs (antidepressants and sodium oxybate). A detail review of the epidemiology, pathophysiology, clinical features, diagnostic evaluations and management of narcolepsy is presented.

Original languageEnglish
Pages (from-to)345-375
Number of pages31
JournalMinerva Pneumologica
Volume48
Issue number4
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Narcolepsy
Sleep
Cataplexy
Sodium Oxybate
REM Sleep
HLA Antigens
REM Sleep Behavior Disorder
Disorders of Excessive Somnolence
Ocular Motility Disorders
Polysomnography
Wakefulness
Sleep Initiation and Maintenance Disorders
Obstructive Sleep Apnea
Migraine Disorders
Age of Onset
Antidepressive Agents
Weight Gain
Cerebrospinal Fluid
Life Style
Epidemiology

Keywords

  • Cataplexy
  • Narcolepsy, diagnosis
  • Narcolepsy, epidemiology
  • Narcolepsy, therapy
  • Sleep

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Zarowski, M., Ali-Dinar, T., & Kothare, S. V. (2009). Narcolepsy. Minerva Pneumologica, 48(4), 345-375.

Narcolepsy. / Zarowski, M.; Ali-Dinar, T.; Kothare, S. V.

In: Minerva Pneumologica, Vol. 48, No. 4, 01.12.2009, p. 345-375.

Research output: Contribution to journalArticle

Zarowski, M, Ali-Dinar, T & Kothare, SV 2009, 'Narcolepsy', Minerva Pneumologica, vol. 48, no. 4, pp. 345-375.
Zarowski M, Ali-Dinar T, Kothare SV. Narcolepsy. Minerva Pneumologica. 2009 Dec 1;48(4):345-375.
Zarowski, M. ; Ali-Dinar, T. ; Kothare, S. V. / Narcolepsy. In: Minerva Pneumologica. 2009 ; Vol. 48, No. 4. pp. 345-375.
@article{a8dcecbfc54a4a03bc2658d928d42c04,
title = "Narcolepsy",
abstract = "Narcolepsy is a life-long neurological, rapid eye movement (REM) sleep disorder characterized by excessive daytime sleepiness, REM intrusions in wakefulness and sleep, and abnormal sleep-wake cycle regulation. Additional symptoms include sleep maintenance insomnia, REM sleep behavior disorders, obstructive sleep apnea, periodic limb movement, weight gain, migraines, and depression. Narcolepsy is not an uncommon disorder, but is underrecognized. It has an estimated prevalence of 0.05{\%}. The age of onset shows two peaks of presentation: in childhood and in adults. Both genetics and environmental factors may be involved in the development of narcolepsy. The history, combined with polysomnography and Multiple Sleep Latency Test, remain the current gold standard in the diagnosis of narcolepsy. Human leukocyte antigen (HLA) typing shows an association with HLA DQB1*0602 in more than 92{\%} of cases. The levels of Hypocretin-1 are undetectable in the cerebrospinal fluid in most patients with narcolepsy with cataplexy. It is highly specific (99.1{\%}) and sensitive (88.5{\%}) for narcolepsy with cataplexy but can also be positive in the normal population (25-30{\%}). Early recognition and treatment can greatly improve the quality of life of patients with narcolepsy. Treatment of narcolepsy includes non-pharmacological (life style changes) and pharmacological (stimulants, modafinil, sodium oxybate) treatment against hypersomnia and anti-cataplectic drugs (antidepressants and sodium oxybate). A detail review of the epidemiology, pathophysiology, clinical features, diagnostic evaluations and management of narcolepsy is presented.",
keywords = "Cataplexy, Narcolepsy, diagnosis, Narcolepsy, epidemiology, Narcolepsy, therapy, Sleep",
author = "M. Zarowski and T. Ali-Dinar and Kothare, {S. V.}",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "48",
pages = "345--375",
journal = "Minerva Pneumologica",
issn = "0026-4954",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Narcolepsy

AU - Zarowski, M.

AU - Ali-Dinar, T.

AU - Kothare, S. V.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Narcolepsy is a life-long neurological, rapid eye movement (REM) sleep disorder characterized by excessive daytime sleepiness, REM intrusions in wakefulness and sleep, and abnormal sleep-wake cycle regulation. Additional symptoms include sleep maintenance insomnia, REM sleep behavior disorders, obstructive sleep apnea, periodic limb movement, weight gain, migraines, and depression. Narcolepsy is not an uncommon disorder, but is underrecognized. It has an estimated prevalence of 0.05%. The age of onset shows two peaks of presentation: in childhood and in adults. Both genetics and environmental factors may be involved in the development of narcolepsy. The history, combined with polysomnography and Multiple Sleep Latency Test, remain the current gold standard in the diagnosis of narcolepsy. Human leukocyte antigen (HLA) typing shows an association with HLA DQB1*0602 in more than 92% of cases. The levels of Hypocretin-1 are undetectable in the cerebrospinal fluid in most patients with narcolepsy with cataplexy. It is highly specific (99.1%) and sensitive (88.5%) for narcolepsy with cataplexy but can also be positive in the normal population (25-30%). Early recognition and treatment can greatly improve the quality of life of patients with narcolepsy. Treatment of narcolepsy includes non-pharmacological (life style changes) and pharmacological (stimulants, modafinil, sodium oxybate) treatment against hypersomnia and anti-cataplectic drugs (antidepressants and sodium oxybate). A detail review of the epidemiology, pathophysiology, clinical features, diagnostic evaluations and management of narcolepsy is presented.

AB - Narcolepsy is a life-long neurological, rapid eye movement (REM) sleep disorder characterized by excessive daytime sleepiness, REM intrusions in wakefulness and sleep, and abnormal sleep-wake cycle regulation. Additional symptoms include sleep maintenance insomnia, REM sleep behavior disorders, obstructive sleep apnea, periodic limb movement, weight gain, migraines, and depression. Narcolepsy is not an uncommon disorder, but is underrecognized. It has an estimated prevalence of 0.05%. The age of onset shows two peaks of presentation: in childhood and in adults. Both genetics and environmental factors may be involved in the development of narcolepsy. The history, combined with polysomnography and Multiple Sleep Latency Test, remain the current gold standard in the diagnosis of narcolepsy. Human leukocyte antigen (HLA) typing shows an association with HLA DQB1*0602 in more than 92% of cases. The levels of Hypocretin-1 are undetectable in the cerebrospinal fluid in most patients with narcolepsy with cataplexy. It is highly specific (99.1%) and sensitive (88.5%) for narcolepsy with cataplexy but can also be positive in the normal population (25-30%). Early recognition and treatment can greatly improve the quality of life of patients with narcolepsy. Treatment of narcolepsy includes non-pharmacological (life style changes) and pharmacological (stimulants, modafinil, sodium oxybate) treatment against hypersomnia and anti-cataplectic drugs (antidepressants and sodium oxybate). A detail review of the epidemiology, pathophysiology, clinical features, diagnostic evaluations and management of narcolepsy is presented.

KW - Cataplexy

KW - Narcolepsy, diagnosis

KW - Narcolepsy, epidemiology

KW - Narcolepsy, therapy

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=77949593938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949593938&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77949593938

VL - 48

SP - 345

EP - 375

JO - Minerva Pneumologica

JF - Minerva Pneumologica

SN - 0026-4954

IS - 4

ER -